clinical trial · NCT05413668
First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
Reveal Pharmaceuticals Inc.·phase1·completed·n = 32
HealthyRVP-001Placebo
brief summary
The objectives of this trial are: 1. To evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers 2. To determine the pharmacokinetics and elimination of RVP-001 in healthy adult volunteers.
started
May 18, 2022
primary completion
Jul 22, 2022
completion
Aug 22, 2022
last updated
Apr 22, 2025
detailed description
The first in human study is intended to evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers, and to determine the pharmacokinetics and elimination of RVP-001 in healthy adult volunteers.
official title
A Single Center, Double-Blinded, Phase 1a Randomized Study to Evaluate Safety and Pharmacokinetics of a New Manganese Based Magnetic Resonance Imaging (MRI) Contrast Agent, RVP-001, in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol